Biotech VC Raises $400 Million ‘Opportunity’ Fund in Sign of Possible Industry Rebound

Atlas Venture Announces $400 Million Third Opportunity Fund

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 4, 2025-

Biotech VC raises $400 million ‘opportunity’ fund in sign of possible industry rebound

Prominent biotech VC firm Atlas Venture has another $400 million to invest in drug companies, it told STAT exclusively. But this time, the new funds are reserved for the startups that are already in its portfolio.  The Cambridge, Mass., firm raised the money for what’s known as an opportunity fund. These funds are focused on promising companies that a VC firm has already invested in, allowing it to boost its ownership of a company and, hopefully…

Atlas Venture raises $400M to support existing portfolio biotechs

Atlas Venture, one of the mainstay biotech venture capital firms, has collected its second batch of money within the past nine months. The Cambridge, MA-based firm reeled in $400 million for its